RPMI-8226 (ATCC® CCL-155™)* cells are a multiple myeloma (MM) cell line originally isolated from the peripheral blood of a 61-year-old female plasmacytoma patient.1,2 The cell line is a protypical MM cell line. It is part of the LL-100 cell line panel, which consists of highly characterized leukemia and lymphoma cell lines for which whole-exosome and RNA sequencing is available.3,4
The RPMI-8226 cell line is considered a bona fide human myeloma cell line. It is negative for Epstein-Barr Virus, negative for CD19, expresses very low levels of CD20, but is positive for CD28 and CD38.5-7 The cells display a mature phenotype consistent with the terminal stage of B-cell differentiation. The cells express high densities of PCA1 and Ki-1, but no HLA-class II antigens and typically no B-cell antigens.8 RPMI-8226 cells produce large amounts of secreted λ-type light chains, but no γ-, α-, or μ-heavy chains or inact immunoglobulins.1
RPMI-8226 cells are widely used in immunology and immune-oncology research. Besides being useful for in vitro studies, the cells exhibit tumorigenicity in vivo in a number of immunocompromised xenograph mouse models.9-11
Don’t see what you need in our catalog? Our scientific team engineers cell lines, viral vectors, and assays and provides as much characterization data as you need to move forward with confidence.